On July 12, 2021, the Board of Directors of Candel Therapeutics, Inc. appointed Diem Nguyen, Ph.D. to fill a newly created vacancy on the Board resulting from the resignation of Carrie Cox from the Board, effective as of the effectiveness of the Company's Registration Statement on Form S-1, as amended (File No. 333-257444) (the Registration Statement). Upon the effectiveness of the Registration Statement on July 26, 2021, Dr. Nguyen became a member of the slate of Class III directors with terms expiring at the 2024 Annual Meeting of Stockholders of the company. The Board has determined that Dr. Nguyen qualifies as an independent director and is qualified to serve under the applicable rules and regulations of the Securities and Exchange Commission (the SEC) and the listing rules of the Nasdaq Stock Market LLC. For her service on the Board, Dr. Nguyen will receive the same compensation as other non-employee directors, as described in the company's final prospectus for its initial public offering, dated July 26, 2021. Dr. Nguyen has also entered into the company's standard form of indemnification agreement.